• UBI will have its work published on the front cover of respected publication
  • Neurotech gets green light for Phase II/III trial
  • Sonic Healthcare’s revenue disappoints

UBI’s work gets published

Universal Biosensors (ASX:UBI) rose 6% this morning after telling the market that work done on its Tn Antigen cancer biosensor has been published in the American Chemical Society Journal “ACS Sensors”.

The work has also been selected as the front cover for the publication.

ACS Sensors is widely recognised as the world’s leading academic journal in the field, and specialises in new and innovative breakthroughs at the forefront of sensor and diagnostic technologies.

Articles published in the Journal have to follow a rigorous international scientific peer-reviewed process.

The published article will be titled “A Rapid Point-of-Care Electrochemical Sensor for the Detection of Cancer Tn Antigen Carbohydrate in Whole Unprocessed Blood.”

It will be written by researchers from Swinburne University of Technology and Deakin University who worked with UBI in the first clinical study of UBI’s Tn Antigen biosensor.

The article provides important details on the science and innovation behind UBI’s Tn Antigen biosensor, which is built upon a novel anti-fouling technology based on lubricin –  a biological lubricant and anti-adhesive protein that naturally occurs in the body.

Lubricin significantly improves the electrochemical signals and detection limits in electrochemical sensors in biological fluids such as blood and saliva.


Neurotech gets green light for Phase II/III trial

Neurotech (ASX:NTI) rose 1.5% after receiving Human Research Ethics Committee (HREC) and Therapeutic Goods Administration (TGA) approvals for its upcoming clinical trial.

The trial is a Phase II/III NTIASD2 clinical trial for children with Autism Spectrum Disorder (ASD).

In the previous open-label Phase I/II trial, NTI has demonstrated significant improvement in ASD children who were administered with NTI’s NTI164 drug.

The Phase II/III NTIASD2 trial will be a randomised, double-blind, placebo-controlled trial that will recruit up to 54 patients with ASD to determine the efficacy and safety of NTI164 versus placebo.

The study comprises an eight-week treatment period, followed by an eight-week open-label maintenance period, followed by a two-week wash-out period.

“Combined with standard non-drug behavioural therapies, NTI164 can be considered a patient enabling drug, by improving daily living and allowing children to integrate into society via significant improvements in socialisation and anxiety,” said Dr Thomas Duthy, executive director of Neurotech.

Sonic’s revenue declines

Diagnostic services giant Sonic Healthcare (ASX:SHL) rose 0.5% despite reporting an 11.7% fall in YTD revenue.

Sonic’s YTD October revenue was $2.726 billion, down from $3.087 billion for the same period a year earlier.

Revenue from Covid-19 related services fell by 65% on a YTD basis.

Sonic says it will not provide an earnings guidance for FY23 at this stage due to Covid-19 related unpredictability.


Share prices today: